Coagulopathy
Conditions
Interventions
The study will consist of a total sample of 140 patients who will undergo liver transplant surgery. Of this total of patients, half of them, that is, 70 patients, will be placed in Group I (placebo) w
D68.9
Sponsors
Hospital de Clinicas de Porto Alegre
Santa Casa de Misericórdia de Porto Alegre
Eligibility
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Only adult ASA III to IV patients, 18 to 70 years old, scheduled for liver transplantation at the Hospital de Clínicas de Porto Alegre, Santa Casa de Porto Alegre and Hospital das Clínicas Faculty of Medicine University of São Paulo.
Exclusion criteria
Exclusion criteria: Patients with a history of acute arterial thrombosis or venous thromboembolism (<1 month), patients with a history of known thrombophilia, Budd-Chiari syndrome, primary biliary cholangitis, primary sclerosing cholangitis, patients with reduced left ventricular function ( ejection fraction <40%), pulmonary hypertension, preoperative pulmonary edema, or severe preoperative hemodynamic changes requiring the use of vasoactive drugs, planned use of tranexamic acid systemically during surgery, hypersensitivity or known allergy to acid tranexamic, history of seizure disorder, patients who have recently suffered a stroke or myocardial infarction (<1 month), patients with subarachnoid hemorrhage in the last 30 days and patients previously undergoing cranial neurosurgery. Patients with chronic dialysis kidney disease or patients in need of a liver-kidney transplant will also be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluate the prevention efficacy of tranexamic acid intravenously in relation to placebo (control - saline) on bleeding in the intraoperative and immediate postoperative (24 hours) in patients undergoing orthotopic liver transplantation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluate the efficacy of tranexamic acid intravenously in relation to placebo (control - saline) on the transfusion rate of blood products in the perioperative period (24 hours) in patients undergoing orthotopic liver transplantation.;Evaluate the efficacy of tranexamic acid intravenously in relation to placebo (control - saline) on the rate of fluid administration in the perioperative period (24 hours) in patients undergoing orthotopic liver transplantation.;Evaluate the effects of tranexamic acid intravenously in relation to placebo (control - saline) on the incidence of thromboembolic events in the perioperative period (up to 30 days) in patients undergoing orthotopic liver transplantation.;Assess the incidence of potential adverse perioperative effects of tranexamic acid intravenously in relation to placebo (control - saline) (up to 30 days) in patients undergoing orthotopic liver transplantation.;Evaluate the effects of tranexamic acid intravenously in relation to placebo (control - saline) on hemodynamic parameters in the perioperative period (24 hours) in patients undergoing orthotopic liver transplantation.;Assess the effects of tranexamic acid intravenously in relation to placebo (control - saline) on perioperative metabolic and gasometric parameters (24 hours) in patients undergoing orthotopic liver transplantation.;Evaluate the efficacy of tranexamic acid intravenously in relation to placebo (control - saline) on the mortality rate (up to 30 days) in patients undergoing orthotopic liver transplantation.;Evaluate the efficacy of tranexamic acid intravenously in relation to placebo (control - saline) on the transfusion rate of blood components in the perioperative period (24 hours) in patients undergoing orthotopic liver transplantation. | — |
Countries
Brazil
Contacts
Public ContactEduarda Martinelli
Outcome results
None listed